J&J’s nipocalimab met primary endpoints in Phase III and II trials for myastheni...
“This is very significant. It’s massive.” Read about the woman suing her employe...
Novartis said late Monday it has agreed to buy German biotech MorphoSys and its ...
The bankruptcy of primary care provider Cano Health, a company once valued at $4...
A Democrat was willing to sign on to legislation that would weaken Medicare's po...
The big takeaway from CMS’ newest proposals for Medicare Advantage: the Biden ad...
Diabetes treatments have improperly listed patents that should be removed, a new...
Monday’s announcement that the parent company of Novo Nordisk plans to buy Catal...
After a months-long fight with Texas Medicaid over coverage of a gene therapy, A...
Regeneron is interested in obesity treatments that combat muscle loss — potentia...
The investment arm of Novo Nordisk’s parent foundation is buying Catalent, a con...
An investment group tied to Novo Nordisk is buying drug manufacturer Catalent fo...
The new obesity drugs are effective but expensive and usually need to be taken f...
Cancer cases around the world are expected to surge 77% by 2050. A new WHO repor...
Why the debate over proposed nursing home staff minimums is particularly unprodu...
A new Medicare Advantage plan rule went largely overlooked, but recent financial...
